CD8 Antibody (JG12) [PE/Cy5.5]
Novus Biologicals, part of Bio-Techne | Catalog # FAB7080PECY55
 
      Conjugate
              Catalog #
              
            Key Product Details
Species Reactivity
                  Cotton Rat
                
                                                                                        Applications
                  Flow Cytometry
                
                                                              Label
            PE/Cy5.5 (Excitation = 488 nm, Emission = 695 nm)
          
        Antibody Source
            Monoclonal Mouse IgG2A Clone # JG12
          
        Concentration
            Please see the vial label for concentration. If unlisted please contact technical services.
          
        Product Specifications
Immunogen
                          NIH‑3T3 mouse embryonic fibroblast cell line transfected with cotton rat CD8 alpha and SP2/O mouse melanoma cell line transfected with cotton rat CD8 alpha.
Accession # AAL55392
        Accession # AAL55392
Specificity
                          Detects cotton rat CD8 alpha in direct ELISAs.
                      
        Clonality
                          Monoclonal
                      
        Host
                          Mouse
                      
        Isotype
                          IgG2A
                      
        Applications for CD8 Antibody (JG12) [PE/Cy5.5]
          Application
        
        
          Recommended Usage
        
      Flow Cytometry
                                                Optimal dilutions of this antibody should be experimentally determined.
                                                            
                  
        Application Notes
      
      
        Optimal dilution of this antibody should be experimentally determined. For optimal results using our Tandem  dyes, please avoid prolonged exposure to light or extreme temperature fluctuations. These can lead to irreversible degradation or decoupling. When staining intracellular targets, specific attention to the fixation and permeabilization steps in your flow protocol may be required. Please contact our technical support team at technical@novusbio.com if you have any questions.
      
    Formulation, Preparation, and Storage
Purification
                          Protein A or G purified from hybridoma culture supernatant
                      
        Formulation
                          PBS
                      
        Preservative
                          0.05% Sodium Azide
                      
        Concentration
                          Please see the vial label for concentration. If unlisted please contact technical services.
                      
        Shipping
                          The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
                      
        Stability & Storage
                          Store at 4C in the dark. Do not freeze.
                      
        Background: CD8
Given its role in the immune system, CD8-deficiency in T-cells is a hallmark of many diseases and pathologies (8-10). Specifically, CD8+ T-cell deficiency is prevalent in chronic autoimmune diseases including multiple sclerosis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, type 1 diabetes mellitus, and Graves' disease (8). Furthermore, cancers or chronic infection can lead to CD8 T-cell exhaustion as the continual antigen presentation and inflammatory signals eventually cause the CD8+ T-cells to lose functionality (9, 10). However, animal models and clinical studies have suggested that T-cells are capable of being reinvigorated using inhibitory receptor blockade resulting in better disease outcomes and these exhausted T-cells may be a potential therapeutic target (9, 10).
Alternative names for CD8 includes CD antigen: CD8a, CD8 antigen, alpha polypeptide (p32), CD8a molecule, CD8A, Leu2 T-lymphocyte antigen, LEU2, MAL, OKT8 T-cell antigen, p32, T cell co-receptor, T8 T-cell antigen, T-cell antigen Leu2, T-cell surface glycoprotein CD8 alpha chain, and T-lymphocyte differentiation antigen T8/Leu-2.
References
1. Littman D. R. (1987). The structure of the CD4 and CD8 genes. Annual review of immunology. https://doi.org/10.1146/annurev.iy.05.040187.003021
2. Naeim F. (2008). Chapter 2- Principles of Immunophenotyping. Hematopathology. https://doi.org/10.1016/B978-0-12-370607-2.00002-8.
3. Gao, G. F., & Jakobsen, B. K. (2000). Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunology today. https://doi.org/10.1016/s0167-5699(00)01750-3
4. UniProt (P01732)
5. UniProt (P01731)
6. Kappes D. J. (2007). CD4 and CD8: hogging all the Lck. Immunity. https://doi.org/10.1016/j.immuni.2007.11.002
7. Gangadharan, D., & Cheroutre, H. (2004). The CD8 isoform CD8alphaalpha is not a functional homologue of the TCR co-receptor CD8alphabeta. Current opinion in immunology. https://doi.org/10.1016/j.coi.2004.03.015
8. Pender M. P. (2012). CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Autoimmune diseases. https://doi.org/10.1155/2012/189096
9. Kurachi M. (2019). CD8+ T cell exhaustion. Seminars in immunopathology. https://doi.org/10.1007/s00281-019-00744-5
10. Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018). CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annual review of medicine. https://doi.org/10.1146/annurev-med-012017-043208
Alternate Names
            CD8, CD8A
          
        Gene Symbol
            CD8A
          
        Additional CD8 Products
Product Documents for CD8 Antibody (JG12) [PE/Cy5.5]
Product Specific Notices for CD8 Antibody (JG12) [PE/Cy5.5]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
    Loading...
  
    Loading...
  
    Loading...
  
    Loading...
  
    Loading...
  
Loading...